Associations between insulin-like growth factor binding protein-2 and insulin sensitivity, metformin, and mortality in persons with T2D
Authors' conclusion
In T2D, high IGFBP-2 associates with low glucose and insulin secretion, is unaffected by metformin treatment, and associates with risk of prior comorbidity and mortality.
Study context
- Population
- Persons with T2D enrolled in the Danish Centre for Strategic Research in T2D
- Participants
- 558 vs 859
- Exposure
- Metformin-treated vs treatment-naive; IGFBP-2 levels and mortality
- Metformin-treatedn = 558
- Treatment-naiven = 859reference
- Outcome
- Association of serum IGFBP-2 with mortality
- Follow-up
- 4.9 (3.9-5.9) years
Methodological detailsDanish Centre for Strategic Research in T2D, registry follow-up
- Danish Centre for Strategic Research in T2D
- Registry follow-up
Main finding
As reported in the abstract
Mortality per doubling in IGFBP-2 concentration · 4.9 (3.9-5.9) years
Estimate (95% CI)
Per doubling in IGFBP-2
unadjusted HR 2.62(2.04–3.37)
Per doubling in IGFBP-2
fully adjusted HR 2.21(1.61–3.01)
Per doubling in IGFBP-2, as printed
- Deaths during follow-up
- 87
Observational data: associations, not effects.
Further findings
IGFBP-2 by metformin treatment, age-adjusted
- Similar IGFBP-2 levels in metformin-treated and treatment-naive
IGFBP-2 and insulin sensitivity indices
- Low IGFBP-2 associated with increased BMI, fasting glucose and C-peptide
IGFBP-2 by comorbidity at enrollment (ng/mL)
- Comorbidities (n=437) vs T2D only
- 343 (213;528) vs. 242 (169;378) ng/mL
Original publication
Associations between insulin-like growth factor binding protein-2 and insulin sensitivity, metformin, and mortality in persons with T2D. Diabetes Res Clin Pract. Published 25 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →